These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 21606101

  • 1. A quantitative analysis of adverse events and "overwarning" in drug labeling.
    Duke J, Friedlin J, Ryan P.
    Arch Intern Med; 2011 May 23; 171(10):944-6. PubMed ID: 21606101
    [No Abstract] [Full Text] [Related]

  • 2. Invited commentary--prescription drug label adverse events: a call for prioritization: comment on "A quantitative analysis of adverse events and 'overwarning' in drug labeling".
    Cheng C, Guglielmo BJ.
    Arch Intern Med; 2011 May 23; 171(10):946-7. PubMed ID: 21606102
    [No Abstract] [Full Text] [Related]

  • 3. Postmarketing modifications in the safety labeling of the new antiepileptics.
    Buck ML, Gurka MJ, Goodkin HP.
    Neurology; 2007 May 01; 68(18):1536-7. PubMed ID: 17470758
    [No Abstract] [Full Text] [Related]

  • 4. Red sky in the morning: modifying prescription drug labels as a result of postmarket surveillance.
    Jacobson JD, Feigal D.
    Food Drug Law J; 2007 May 01; 62(3):529-46. PubMed ID: 17915395
    [No Abstract] [Full Text] [Related]

  • 5. Improving drug safety monitoring.
    Karande S, Gogtay NJ, Kshirsagar NA.
    Indian Pediatr; 2003 Dec 01; 40(12):1167-75. PubMed ID: 14722367
    [Abstract] [Full Text] [Related]

  • 6. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
    O'Reilly JT.
    Food Drug Law J; 2007 Dec 01; 62(3):559-72. PubMed ID: 17915397
    [No Abstract] [Full Text] [Related]

  • 7. Evaluating drugs after their approval for clinical use.
    Ray WA, Griffin MR, Avorn J.
    N Engl J Med; 1993 Dec 30; 329(27):2029-32. PubMed ID: 8018139
    [No Abstract] [Full Text] [Related]

  • 8. Flight 483 now boarding.
    Czap A.
    Altern Med Rev; 2010 Sep 30; 15(3):183-5. PubMed ID: 21155619
    [No Abstract] [Full Text] [Related]

  • 9. FDA post-marketing safety decisions.
    Klein DF.
    J Clin Psychiatry; 2006 Aug 30; 67(8):1305-6. PubMed ID: 16965212
    [No Abstract] [Full Text] [Related]

  • 10. The drug safety system conundrum.
    Tiedt TN.
    Food Drug Law J; 2007 Aug 30; 62(3):547-558. PubMed ID: 17915396
    [No Abstract] [Full Text] [Related]

  • 11. Form for reporting serious adverse events and product problems with human drug and biological products and devices; availability--FDA. Notice.
    Fed Regist; 1993 Jun 03; 58(105):31596-614. PubMed ID: 10171452
    [Abstract] [Full Text] [Related]

  • 12. Lessons from cisapride.
    CMAJ; 2001 May 01; 164(9):1269, 1271. PubMed ID: 11341130
    [No Abstract] [Full Text] [Related]

  • 13. Xyrem (sodium oxybate) postmarketing adverse event reporting system.
    Wang YG.
    Sleep Med; 2010 Jun 01; 11(6):595; author reply 595-6. PubMed ID: 20362501
    [No Abstract] [Full Text] [Related]

  • 14. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL.
    J Natl Cancer Inst; 2005 Jun 15; 97(12):872-3. PubMed ID: 15956645
    [No Abstract] [Full Text] [Related]

  • 15. "Safer, but not safe enough".
    Crombie HD.
    Conn Med; 2006 Jun 15; 70(10):645. PubMed ID: 17190395
    [No Abstract] [Full Text] [Related]

  • 16. Cisapride and patient information leaflets.
    Sukkari SR, Sasich LD.
    CMAJ; 2001 May 01; 164(9):1276-8; author reply 1278-9. PubMed ID: 11341134
    [No Abstract] [Full Text] [Related]

  • 17. Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials.
    Seruga B, Sterling L, Wang L, Tannock IF.
    J Clin Oncol; 2011 Jan 10; 29(2):174-85. PubMed ID: 21135271
    [Abstract] [Full Text] [Related]

  • 18. Reporting of adverse drug events: a key to postmarketing drug safety.
    Rheinstein PH.
    Am Fam Physician; 1992 Sep 10; 46(3):873-4. PubMed ID: 1514478
    [No Abstract] [Full Text] [Related]

  • 19. The black box warning.
    Abourjaily HM, Rosenberg M.
    J Mass Dent Soc; 2002 Sep 10; 51(3):54-6. PubMed ID: 12380043
    [No Abstract] [Full Text] [Related]

  • 20. Strategy for surveillance of adverse drug events.
    Bright RA.
    Food Drug Law J; 2007 Sep 10; 62(3):605-16. PubMed ID: 17915403
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.